If the rivastigmine patch is not helping, the next step is a medication and diagnosis review—not automatically a higher dose or a new drug. A clinician should confirm correct use, assess whether the trial was adequate, and weigh switching, adding memantine, or gradually stopping treatment. Rivastigmine is a cholinesterase inhibitor used for Alzheimer's dementia and mild-to-moderate Parkinson's disease dementia. It does not cure dementia, and some people receive no noticeable benefit.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Was the patch given a fair trial?
- Could something else explain the decline?
- What medication options come next?
- When does stopping rivastigmine make sense?
- Side effects that need prompt review
Was the patch given a fair trial?
The first check is whether the patch was used correctly and long enough. The FDA label starts treatment at 4.6 mg per 24 hours, allows dose increases after at least four weeks, and identifies 9.5 mg per 24 hours as the minimum effective dose. Only one patch should be worn at a time, according to the FDA's May 2024 Exelon Patch label.
Before deciding that treatment failed, review: "Helping" does not always mean visible improvement. In trials lasting 6 to 12 months, some people improved or remained stable, some declined more slowly, and others received no benefit. Because dementia progresses, slower decline may be difficult to recognize without comparing function over time.
- The dose and how long the person has received it
- Whether patches were changed on schedule
- Whether the old patch was removed before applying a new one
- Changes in cognition or daily function since treatment began
- Side effects, missed doses, and other medications
Could something else explain the decline?
Apparent treatment failure should prompt a review of the dementia diagnosis. Rivastigmine's approved uses include Alzheimer's dementia of any severity and mild-to-moderate Parkinson's disease dementia; another dementia type may respond differently. A clinician should also look for other contributors to worsening, including stroke, infection, sleep problems, and medication effects.
These issues can occur alongside dementia and may make the patch appear ineffective. Bring a current medication list and a brief timeline of changes to the appointment. Note when the decline began, whether it was gradual, and whether it followed an illness, medication change, or disrupted sleep.
What medication options come next?
For Alzheimer's disease, a clinician may consider switching from rivastigmine to donepezil or galantamine. However, the National Institute on Aging explains that these cholinesterase inhibitors work similarly, so switching may not produce a meaningful difference—although an individual may respond better to another drug (NIA treatment guidance). For moderate-to-severe Alzheimer's, memantine is another evidence-based option.
It works differently and may be prescribed with a cholinesterase inhibitor. NICE recommends adding memantine in moderate disease and offering it in severe disease in its dementia treatment recommendations. Lecanemab and donanemab are not general replacements for an ineffective patch. They are approved for early Alzheimer's—mild cognitive impairment or mild dementia—require confirmation of amyloid, and carry a risk of brain swelling or bleeding that requires MRI monitoring.
When does stopping rivastigmine make sense?
Stopping may be reasonable when there was never a meaningful benefit, an earlier benefit appears lost, side effects outweigh benefits, or dementia has become severe or end-stage. This should be a shared decision that considers cognition, daily function, treatment burden, and the person's care goals. Deprescribing guidance supports a monitored trial of gradual withdrawal rather than an abrupt, unobserved stop.
If cognition or function noticeably deteriorates after withdrawal, restarting may be appropriate, according to a 2022 deprescribing review in Alzheimer's & Dementia. Agree in advance on what will be monitored and who will report changes. That makes it easier to distinguish a meaningful decline from ordinary day-to-day variation.
Side effects that need prompt review
Contact the prescribing clinician promptly for troublesome nausea, vomiting, diarrhea, appetite loss, weight loss, or significant skin reactions. Prolonged vomiting or diarrhea can lead to dehydration.
Check the skin and remove the previous patch before applying the next one. Wearing more than one patch has caused serious overdose events, so any accidental duplicate application requires prompt clinical guidance.
